Keyphrases
Clinical Analysis
100%
Systematic Meta-analysis
100%
Certainty of Evidence
56%
Myotonic Dystrophy
50%
Bifurcation Complex
50%
Cardiac Involvement
50%
Natural History
50%
Lifelong Follow-up
50%
COVID-19 Progression
50%
Optical Coherence Tomography
50%
COVID-19 Prevention
50%
Optical Coherence Tomography Angiography (OCT-A)
50%
Severe Disease
50%
Percutaneous Coronary Intervention
50%
Drug Intervention
50%
Bifurcation Lesion
50%
Beneficial Effects
50%
Harmful Effects
50%
Tricyclic Antidepressants
50%
Major Depressive Disorder
50%
Small Vessel Disease
50%
Obesity
50%
Nationwide Registry
50%
Coronary Risk Factors
50%
Body Mass Index
50%
Obstructive Coronary Artery Disease
50%
Serious Adverse Events
48%
Molnupiravir
30%
European Medicines Agency
30%
Meta-analysis
22%
Risk of Death
20%
Nirmatrelvir
20%
Relative Risk
20%
Ritonavir
20%
Echocardiography
18%
Quality of Life
18%
Placebo
18%
HDRS-17
18%
Angiography
17%
Intervention Group
17%
Prospero
16%
Risk of Bias
16%
High Risk
16%
Late Follow-up
12%
Depressive Symptoms
12%
Clinical Outcomes
12%
Multivariate Logistic Regression
11%
Comorbidity
10%
Clinical Trials
10%
Disease Progression
10%
Medicine and Dentistry
Percutaneous Coronary Intervention
50%
Myotonic Dystrophy
50%
Optical Coherence Tomography
50%
Echocardiography
50%
Angiography
50%
Sequential Analysis
50%
Tricyclic Antidepressant
50%
Systematic Review with Meta-Analysis
50%
Major Depressive Episode
50%
Sudden Cardiac Death
33%
Diagnosis
33%
Holter Monitoring
33%
Adverse Event
25%
Placebo
25%
Quality of Life
18%
Electrocardiogram
16%
Cardiac Dysrhythmia
16%
Left Ventricular Systolic Dysfunction
16%
Symptom
16%
Patient Care
16%
Electronic Health Record
16%
Prevalence
16%
ECG Leads
16%
Patient Characteristics
16%
Ambulatory Electrocardiography
16%
Meta-Analysis
12%
Depression
12%
Student T Test
6%
Hamilton Rating Scale for Depression
6%
Randomized Clinical Trial
6%
Major Adverse Cardiac Event
5%
Coronary Artery
5%
Pharmacology, Toxicology and Pharmaceutical Science
Disease
100%
Adverse Event
75%
Molnupiravir
50%
Obesity
50%
Major Depression
50%
Coronary Artery Disease
50%
Tricyclic Antidepressant
50%
Coronary Risk
50%
Ritonavir
33%
Nirmatrelvir
33%
Prevalence
30%
Placebo
25%
Comorbidity
16%
SARS Coronavirus
16%
Clinical Trial
16%
All Cause Mortality
16%
Disease Exacerbation
16%
Depression
12%
Underweight
10%
Randomized Clinical Trial
6%
